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Abstract The effects of Spirulina maxima supplementation
on calcium, magnesium, iron, and zinc status were studied in a
double-blind placebo-controlled trial of 50 obese subjects
with treated hypertension, each randomized to receive 2 g of
spirulina or a placebo daily for 3 months. At baseline and after
treatment, the calcium, magnesium, iron, and zinc concentra-
tion in plasma was assessed. It was found that 3 months of S.
maxima supplementation resulted in a significant decrease in
the iron level in the plasma of obese patients. In conclusion,
this is the first clinical study on the influence of spirulina
supplementation on mineral status in obese patients with hy-
pertension. Spirulina supplementation affects the iron status of
obese Caucasians with well-treated hypertension.
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Introduction
Obesity is associated with an impairment of the body’s min-
eral status. Multiple studies have indicated that obesity is
accompanied by altered iron homeostasis [1]. At the same
time, weight reduction has been associatedwith improved iron
metabolism [2]. It has been demonstrated that serum magne-
sium content decreases in experimental [3] and clinical studies
[4, 5]. Moreover, it has been proposed that magnesium defi-
ciency in obese subjects may contribute to hypertension [6]
and insulin resistance [5]. Recent data also indicate an associ-
ation between inadequate calcium intake and increased body
weight [7]. It has been also proposed that increased consump-
tion of calcium in the diet may result in improvements in
obesity and hypertension [8]. The mechanisms of antiobesity
action of dietary calcium may involve decreased fat absorp-
tion, regulation of adipocyte proliferation, and apoptosis [9].
Finally, zinc concentration in both plasma and the erythro-
cytes of obese individuals was significantly lower than in lean
individuals [10]. Experimental studies also provide additional
data on the role of zinc deficiency in obesity pathogenesis in
high-fat fed mice [11]. Taking into account the possible role of
impaired zinc balance in hypertension [12], obesity-associated
zinc deficiency may be an additional link between these two
pathologies. It was found in another study that improvements
in zinc status were associated with increases in insulin sensi-
tivity in obese patients [13, 14].
Blue-green freshwater algae may be a good source of min-
erals for obese people, and especially of calcium and iron, due
to their substantial levels [15, 16]. Moreover, green algae
show promising antiobesity properties. Spirulina is widely
used in functional nutrition and medicine due to its antioxi-
dant, anti-inflammatory, anticancer, and immunostimulatory
activities [17]. At the same time, these microalgae are able
to accumulate significant amounts of trace elements, thus
serving as a supplemental nutritional source of essential ele-
ments [18]. Moreover, the metal-accumulating ability of spi-
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The hypothesis in the present study is that oral supplemen-
tation with spirulina has an influence on mineral status in
obese hypertensive patients receiving standard antihyperten-
sive treatment. Patients were therefore randomized to receive
2 g of Spirulina maxima or a matching placebo daily, in order
to measure the concentration of calcium, magnesium,




The study protocol was approved by the Research Ethics
Committee of Poznań University of Medical Sciences, regis-
tered as case no. 599/12. Informed consent was obtained from
all patients. The study was performed in accordance with the
Declaration of Helsinki.
Among the 142 registered patients with hypertension and
obesity screened in our outpatient clinic, a total of 50 (25 men,
25 women) were enrolled to the study.
The inclusion criteria were body mass index (BMI) equal
to or greater than 30 kg/m2, age 25 to 60 years, stable body
weight (<3 kg self-reported change during the previous
3 months), and well-controlled hypertension (meaning systol-
ic blood pressure (SBP) less than 160 mmHg and diastolic
blood pressure (DBP) less than 100 mmHg) with stable treat-
ment for at least 6 months.
The exclusion criteria were secondary obesity or sec-
ondary hypertension; diabetes; a history of coronary artery
disease, stroke, congestive heart failure, or malignancy; a
history of the use of any dietary supplements within the
3 months prior to the study; a current need for modification
of antihypertensive therapy; abnormal liver or kidney func-
tion; any clinically significant process; a history of infec-
tion in the month prior to the study; nicotine or alcohol
abuse; or other condition that, in the opinion of the inves-
tigators, would make participation not in the best interest
of the patient or could prevent, limit, or confound the
protocol-specified efficacy assessments.
Study Design
The study was designed as a randomized double-blind
placebo-controlled trial with two parallel groups.
Randomization was performed by an independent
statistician. The participants were randomly assigned
(in a 1:1 ratio) to receive with their morning meal for 3 months
four capsules of either Hawaiian spirulina (Cyanotech
Corporation, HI, USA) or a placebo. All supplements
were packed in bottles without labeling. The Hawaiian
spirulina capsules each contained 0.5 g of S. maxima
(60–70 % protein, gamma-linolenic acid (GLA), beta caro-
tene, iron, and phycocyanin (PC)). The placebo consisted of
pure microcrystalline cellulose. All patients were advised to
continue their habitual diet and exercise patterns throughout
the study. The intention-to-treat (ITT) population consisted of
50 patients.
Anthropometric and Blood Pressure Measurements
During the anthropometric measurements, the patients
wore lightweight clothing and no shoes. Weight was
measured to the nearest 0.1 kg and height to the nearest
0.1 cm. Obesity was defined as a BMI of 30 kg/m2 or
greater (WHO, 1995). Blood pressure was measured
seated, according to the guidelines of the European
Society of Hypertension [20], using a digital electronic
tensiometer (model 705IT, Omron Corporation, Kyoto,
Japan). Hypertension was defined as the average of three
measurements of arterial blood pressure obtained after
10 min of physical rest by the patients (twice at two differ-
ent visits in the same month).
Biochemical Measurements
Blood samples were taken from each participant following an
overnight fast and after lying in a supine position for 30 min.
The levels of calcium, magnesium, iron, and zinc in plasma
were determined by flame atomic absorption spectrometry
(with a Zeiss AAS-3 spectrometer with deuterium background
correction). In order to obtain the concentration of the plasma
elements, the samples were diluted (v/v 1:1) as follows: for
iron and zinc analyses, 0.01 % Triton X-100 (Merck) was
used, while for the calcium and magnesium analysis, aqueous
solutions consisting of 0.01 % Triton X-100 (Merck) and
0.05 % lanthanum chloride (Merck) were used. The amounts
of iron, zinc, calcium, and magnesium in the plasma samples
were determined at the following respective wavelengths:
248.3, 213.9, 422.7, and 285.2 nm. The accuracy of the meth-
od was verified using a certified reference material (HUM
ASY CONTROL 2, Randox) and was 95, 99, 94, and 99 %
for calcium, magnesium, iron, and zinc, respectively.
Dietary and Supplement Intake
Every 14 days, and also 3 days before the laboratory tests,
dietary intake was assessed on the basis of dietary intake in-
terviews (24-h recall). The level of nutrients in the daily diet
was evaluated using a dietetics computer program (Dieta 5.0,
2011). The intake of nutrients and caffeine consumption dur-
ing the study were constant and comparable between the
groups. Physical activity was constant and unchanged in all
subjects at the beginning of and after treatment.
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In this study, a single daily dosage of supplement was used
in order to facilitate the patients taking it. During the interview
with each patient on the first day of the study, the physician
described taking the daily spirulina supplement and its bene-
fits. Every 14 days, the patient visited the dietician to record
the number of pills consumed over the previous 2-week peri-
od. During the first visit to the dietician, each patient received
a diary in which to enter the time the supplement was taken
each day. On subsequent visits, the diary was checked by
either a dietician or a physician. The investigators maintained
a log of all pills dispensed and returned. The drugs supplied to
each subject were accounted for throughout the study. The
level of compliance required was 90 %.
Statistical Analysis
It was calculated that a sample size of at least 20 patients in
each group would yield at least an 80 % chance of detecting a
treatment effect as being statistically significant at the 0.05
alpha level. The results are given as mean values. Statistical
calculations were performed using Statistica 10.0 software
(StatSoft, Inc., Tulsa, OK, USA). The normality test was per-
formed to assess normal distribution within the data.
Statistical analysis was carried out using a factorial ANOVA.
Mann-Whitney U test was used to assess the differences be-
tween the groups at baseline. ITTanalysis was performed. A p
value of less than 0.05 was regarded as significant.
Results
The baseline characteristics of both groups are shown in
Table 1. There were no statistically significant differ-
ences between the two treatment groups prior to the
study. All subjects completed the study, and no signifi-
cant changes in diets, physical activity, or antihyperten-
sive treatment were recorded.
The amount of minerals in S. maxima is shown in Table 2.
The values of the concentration of the minerals in plasma in
the spirulina and placebo groups, both before and after treat-
ment, are summarized in Table 3, along with the p values for
the Btreatment^ and Btime^ factors and their interactions, as
obtained from the ANOVA analysis. A statistically significant
interaction between treatment and time factors (with both fac-
tors being statistically significant) was observed only for the
iron level. The iron level was found to be significantly lower
in the spirulina group than in the placebo group.
Following treatment, the concentration of calcium, magne-
sium, and zinc in plasma was not changed markedly in either
of the groups.
Discussion
The data indicate that spirulina consumption resulted in
significantly decreased serum iron concentrations.
Hypothetically, this effect may occur as a result of the
iron-chelating activity of spirulina. In particular, it has
been demonstrated that phycocyanin isolated from
Spirulina platensis extract is capable of binding ferrous
ions (from FeSO4) and ferric ions (from FeCl3) [21].
The presence of phycocyanin in other spirulina species,
including the S. maxima [22] used in the current study,
supports this hypothesis. Furthermore, it is known that
blue-green algae bioaccumulate heavy metals and they
Table 2 Concentration of minerals in Hawaiian spirulina supplement
Minerals In 100 g of powder In 2 g (4 capsules)
of powder
Ca (mg) 583.3 11.7
Mg (mg) 746.7 14.9
Fe (mg) 175.3 3.5
Zn (mg) 57.3 1.2
Table 1 Baseline characteristics of Spirulina group and Placebo group
(value are means ± SD)





Male (n) 12 13
Female (n) 13 12
Age (year) 49.3 ± 8.7 50.2 ± 7.2 NS
Time since diagnosis of
hypertension (year)







BMI (kg/m2) 33.5 ± 6.7 33.3 ± 6.2 NS
SBP (mmHg) 148 ± 15 151 ± 15 NS
DBP (mmHg) 84 ± 9 85. ± 9 NS
Ca (mmol/L) 3.4 ± 0.3 3.3 ± 0.2 NS
Mg (mmol/L) 0.8 ± 0.1 0.8 ± 0.1 NS
Fe (μmol/L) 16.6 ± 3.8 15.8 ± 2.6 NS
Zn (μmol/L) 10.0 ± 3.5 10.7 ± 2.5 NS
ACEI angiotensin-converting enzyme inhibitor, CCB calcium channel
blocker, NS not statistically significant, BMI body mass index, SBP sys-
tolic blood pressure,DBP diastolic blood pressure, SD standard deviation
1Differences were tested using Mann-Whitney U test
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act as bioadsorbents for them [23, 24]. Therefore, spirulina
may decrease absorption of iron from food. Moreover,
lower bioavailability of iron may be partly caused by in-
teraction between heavy metals in spirulina and iron, be-
cause as it is known, e.g., cadmium inhibits iron
absorption.
There is a growing body of data on the influence of
spirulina on metabolic syndrome and its components. In
particular, consumption of spirulina in a mouse model of
metabolic syndrome based on monosodium glutamate in-
jection resulted in decreased serum lipids and leptin con-
centrations. Moreover, spirulina has been shown to reduce
liver and adipose tissue inflammation, and even more ef-
fective than pioglitazone [25]. Similar results have been
observed in a recent study [26]. The earlier study also
demonstrated a protective effect of spirulina against
fructose-induced fatty liver formation [27]. Existing clini-
cal studies conform to the experimental data. It has been
shown that the intake of 2.8 g of spirulina thrice a day
results in a significant reduction in body weight [28]. A
report on three cases of nonalcoholic fatty liver disease
indicated the efficacy of S. maxima consumption in im-
proving metabolic and ultrasonographic parameters [29]. S.
maxima is also considered a potential antiobesity drug
[30]. Taking into account the role of oxidative stress and
inflammation in the pathogenesis of obesity and metabolic
syndrome, the antioxidant and anti-inflammatory properties
of spirulina [31] may mediate the observed protective
effect.
A number of studies have highlighted the role of
impaired iron homeostasis in metabolic syndrome [32]
and its components , such as obesi ty [33] and
nonalcoholic fatty liver disease [34]. Moreover, iron
chelation has been shown to be efficient in the preven-
tion of adipocyte hypertrophy, oxidative stress, and in-
flammation [35]. In previous studies, a deficit of iron in
western diet, high in fat and sugar, improves lipid and
carbohydrate metabolism [36]. In clinical trial, it was
found that phlebotomy, with consecutive reduction of
body iron stores, lowered blood pressure and resulted
in improvements in markers of cardiovascular risk and
glycemic control in patients with metabolic syndrome
[37]. It is claimed that iron depletion upregulates glu-
cose uptake and increases insulin receptor activity in
hepatocytes and that the main mechanisms responsible
for improving carbohydrate metabolism are associated
with the inhibition of oxidative stress [36]. In the light
of the recent finding, it may be supposed that the ob-
served protective effect of spirulina in metabolic syn-
drome and obesity may be mediated by the improve-
ment of iron homeostasis and the prevention of iron
overload.
Unquestionably, this study has some limitations: the study
group is rather small and only selected minerals were deter-
mined. In addition, the minerals were measured only in serum
and the concentrations ofmineral in erythrocytes or urine were
not assessed. Moreover, the association between mineral sta-
tus and body mass, blood pressure, and other biochemical
parameters was not determined. The evaluation of these rela-
tionships would allow a wider discussion on the impact of
spirulina treatment on the mineral status in obesity and
hypertension.
In conclusion, treatment with S. maxima resulted in de-
creased serum iron levels in hypertensive obese adults.
Table 3 Changes in mineral status during the supplementation in the spirulina and placebo groups












Intention-to-treat population, n = 50
Ca (mmo/L) Mean ± SD 3.41 ± 0.27 3.25 ± 0.20 3.55 ± 0.32 3.31 ± 0.33 0.202 0.106 0.122
Median 3.43 3.27 3.53 3.29
Mg (mmol/L) Mean ± SD 0.75 ± 0.07 0.80 ± 0.11 0.75 ± 0.10 0.78 ± 0.09 0.288 0.203 0.102
Median 0.74 0.78 0.75 0.79
Fe (μmol/L) Mean ± SD 16.63 ± 3.75 15.84 ± 2.55 12.98 ± 2.75 16.11 ± 3.12 0.008 0.008 0.001
Median 16.58 15.90 13.75 15.98
Zn (μmol/L) Mean ± SD 10.03 ± 3.54 10.71 ± 2.50 9.78 ± 2.14 10.92 ± 1.81 0.517 0.105 0.418
Median 9.09 9.30 9.36 9.38
Data are arithmetic mean ± SD
SD standard deviation, NS not significant
Italic values indicate ANOVA test, significant differences at P < .05
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However, further in vivo and in vitro studies are required to
estimate the exact mechanisms of the influence of spirulina
consumption on iron homeostasis in obesity.
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